J&J/Bayer’s Once-Daily Rivaroxaban Superior To Lovenox In Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J/Bayer are on track to file for venous thromboembolism indication in U.S. in 2008, while Bristol/Pfizer’s apixaban NDA filing is slated for second half of 2009, firms tell “The Pink Sheet” DAILY.
You may also be interested in...
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.
J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market
Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.